Efficacy of an intravenous low-molecular-weight dermatan sulphate (Desmin) in patients with acute proximal deep venous thrombosis and silent pulmonary embolism. A pilot study.
Ten patients affected by proximal deep venous thrombosis were treated in an open study with a low-molecular-weight dermatan sulphate (Desmin), administered at doses of 400 mg (intravenous bolus) followed by 1200 mg/day infused intravenously for 10 days, without activated partial thromboplastin adjustment. The evolution of the deep vein thrombosis and the presence of silent pulmonary embolism were evaluated by phleboscintigraphy and lung scan, performed before treatment and after 10 days of treatment, and by repeated echocolour-Doppler examination (every 2 days during treatment). The evolution of deep vein thrombosis showed a considerable improvement; similarly, lung scan showed a substantial reperfusion of lung, with regression of perfusional deficit. Repeated echocolour-Doppler examination of the deep venous system during treatment did not document further thrombus extension in any patient. Tolerance and safety were excellent. No adverse effects were observed. These preliminary results indicate that the tested dose of Desmin can be effective in treating deep vein thrombosis and silent pulmonary embolism.
Venosi
S
S
Second Department of Vascular Surgery, La Sapienza University, Rome, Italy.
Zamboni
V
V
Irace
L
L
Stumpo
R
R
Massa
R
R
Palazzini
E
E
Valentini
F B
FB
D000208:Acute Disease; D003893:Desmin / Q000627:therapeutic use*; D005260:Female; D005268:Femoral Vein; D006801:Humans; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D010865:Pilot Projects; D011152:Popliteal Vein; D011655:Pulmonary Embolism / Q000188:drug therapy*; D013927:Thrombosis / Q000188:drug therapy*
D003893:Desmin